Cases & Deals

  • Home
  • Practices
  • Purdue Pharma successfully resolves Hatch-Waxman claims against companies seeking to make generic version of transdermal patch Butrans®

Share

Purdue Pharma successfully resolves Hatch-Waxman claims against companies seeking to make generic version of transdermal patch Butrans®

October 2016

Client(s) Purdue Pharma L.P.

Jones Day client Purdue Pharma L.P. successfully resolved a patent infringement action it brought under the Hatch-Waxman Act against two companies that sought FDA approval to market a generic version of Purdue's Butrans® product prior to the expiration of certain patents owned by Purdue. Butrans® is a transdermal patch that delivers buprenorphine, a potent medication used for the treatment of chronic pain.

Purdue Pharma L.P. v. Watson Laboratories, Inc., C.A. No. 14-1227 (D. Del.) (SLR) (SRF)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.